Macquarie Group LTD Iveric Bio, Inc. Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $9,653 - $19,091	-1,027 Reduced 12.83%	6,978 $144,000
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $63,639 - $131,884	6,978 Added 679.45%	8,005 $77,000
Q4 2021 Feb 11, 2022	SELL	$13.83 - $18.78 $18,615 - $25,277	-1,346 Reduced 56.72%	1,027 $17,000
Q3 2021 Nov 12, 2021	SELL	$7.07 - $17.5 $17,477 - $43,260	-2,472 Reduced 51.02%	2,373 $39,000
Q2 2021 Aug 13, 2021	BUY	$5.69 - $7.17 $27,568 - $34,738	4,845 New	4,845 $31,000

Q2 2020 Aug 11, 2020	SELL	$3.06 - $6.6 $34,348 - $74,085	-11,225 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $31,766 - $94,739	11,225 New	11,225 $39,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.